Literature DB >> 33633548

Administration of N-acetylcysteine Plus Acetylsalicylic Acid Markedly Inhibits Nicotine Reinstatement Following Chronic Oral Nicotine Intake in Female Rats.

María Elena Quintanilla1, Paola Morales1,2, Fernando Ezquer3, Marcelo Ezquer3, Mario Herrera-Marschitz1, Yedy Israel1.   

Abstract

BACKGROUND: Nicotine is the major addictive component of cigarette smoke and the prime culprit of the failure to quit smoking. Common elements perpetuating the use of addictive drugs are (i) cues associated with the setting in which drug was used and (ii) relapse/reinstatement mediated by an increased glutamatergic tone (iii) associated with drug-induced neuroinflammation and oxidative stress. AIMS: The present study assessed the effect of the coadministration of the antioxidant N-acetylcysteine (NAC) plus the anti-inflammatory acetylsalicylic acid (ASA) on oral nicotine reinstatement intake following a post-deprivation re-access in female rats that had chronically and voluntarily consumed a nicotine solution orally. The nicotine-induced oxidative stress and neuroinflammation in the hippocampus and its effects on the glutamate transporters GLT-1 and XCT mRNA levels in prefrontal cortex were also analyzed.
RESULTS: The oral coadministration of NAC (40 mg/kg/day) and ASA (15 mg/kg/day) inhibited by 85% of the oral nicotine reinstatement intake compared to control (vehicle), showing an additive effect of both drugs. Acetylsalicylic acid and N-acetylcysteine normalized hippocampal oxidative stress and blunted the hippocampal neuroinflammation observed upon oral nicotine reinstatement. Nicotine downregulated GLT-1 and xCT gene expression in the prefrontal cortex, an effect reversed by N-acetylcysteine, while acetylsalicylic acid reversed the nicotine-induced downregulation of GLT-1 gene expression. The inhibitory effect of N-acetylcysteine on chronic nicotine intake was blocked by the administration of sulfasalazine, an inhibitor of the xCT transporter.
CONCLUSION: Nicotine reinstatement, following post-deprivation of chronic oral nicotine intake, downregulates the mRNA levels of GLT-1 and xCT transporters, an effect reversed by the coadministration of N-acetylcysteine and acetylsalicylic acid, leading to a marked inhibition of nicotine intake. The combination of these drugs may constitute a valuable adjunct in the treatment of nicotine-dependent behaviors.
Copyright © 2021 Quintanilla, Morales, Ezquer, Ezquer, Herrera-Marschitz and Israel.

Entities:  

Keywords:  N-acetylcysteine; acetylsalicylic acid; nicotine; oxidative stress; reinstatement

Year:  2021        PMID: 33633548      PMCID: PMC7902020          DOI: 10.3389/fnbeh.2020.617418

Source DB:  PubMed          Journal:  Front Behav Neurosci        ISSN: 1662-5153            Impact factor:   3.558


  89 in total

1.  Smokers can learn to influence their urge to smoke.

Authors:  M Dols; B Willems; M van den Hout; R Bittoun
Journal:  Addict Behav       Date:  2000 Jan-Feb       Impact factor: 3.913

2.  Prefrontal glutamate release into the core of the nucleus accumbens mediates cocaine-induced reinstatement of drug-seeking behavior.

Authors:  Krista McFarland; Christopher C Lapish; Peter W Kalivas
Journal:  J Neurosci       Date:  2003-04-15       Impact factor: 6.167

3.  Lasting reduction of nicotine-seeking behavior by chronic N-acetylcysteine during experimental cue-exposure therapy.

Authors:  Federico Moro; Giuseppe Giannotti; Lucia Caffino; Claudio Marcello Marzo; Angelo Di Clemente; Fabio Fumagalli; Luigi Cervo
Journal:  Addict Biol       Date:  2019-05-27       Impact factor: 4.280

4.  Effects of chronic inhalation of electronic cigarettes containing nicotine on glial glutamate transporters and α-7 nicotinic acetylcholine receptor in female CD-1 mice.

Authors:  Fawaz Alasmari; Laura E Crotty Alexander; Jessica A Nelson; Isaac T Schiefer; Ellen Breen; Christopher A Drummond; Youssef Sari
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-03-27       Impact factor: 5.067

5.  Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking.

Authors:  Megan M Moran; Krista McFarland; Roberto I Melendez; Peter W Kalivas; Jeremy K Seamans
Journal:  J Neurosci       Date:  2005-07-06       Impact factor: 6.167

6.  MEMRI is a biomarker defining nicotine-specific neuronal responses in subregions of the rodent brain.

Authors:  Aditya N Bade; Howard E Gendelman; Michael D Boska; Yutong Liu
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

7.  TNF-induced activation of the Nox1 NADPH oxidase and its role in the induction of necrotic cell death.

Authors:  You-Sun Kim; Michael J Morgan; Swati Choksi; Zheng-Gang Liu
Journal:  Mol Cell       Date:  2007-06-08       Impact factor: 17.970

8.  Cigarette smoke and nicotine effects on brain proinflammatory responses and behavioral and motor function in HIV-1 transgenic rats.

Authors:  Walter Royal; Adem Can; Todd D Gould; Ming Guo; Jared Huse; Myles Jackson; Harry Davis; Joseph Bryant
Journal:  J Neurovirol       Date:  2018-04-11       Impact factor: 2.643

9.  Behavioral and Biochemical Impact of Chronic Unpredictable Mild Stress on the Acquisition of Nicotine Conditioned Place Preference in Rats.

Authors:  G Biala; K Pekala; A Boguszewska-Czubara; A Michalak; M Kruk-Slomka; K Grot; B Budzynska
Journal:  Mol Neurobiol       Date:  2017-05-08       Impact factor: 5.590

10.  N-acetylcysteine amide provides neuroprotection via Nrf2-ARE pathway in a mouse model of traumatic brain injury.

Authors:  Yuan Zhou; Han-Dong Wang; Xiao-Ming Zhou; Jiang Fang; Lin Zhu; Ke Ding
Journal:  Drug Des Devel Ther       Date:  2018-12-04       Impact factor: 4.162

View more
  1 in total

Review 1.  Neuroimmune Mechanisms as Novel Treatment Targets for Substance Use Disorders and Associated Comorbidities.

Authors:  Mark D Namba; Jonna M Leyrer-Jackson; Erin K Nagy; M Foster Olive; Janet L Neisewander
Journal:  Front Neurosci       Date:  2021-04-15       Impact factor: 4.677

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.